In vivo pre-treatment with Bortezomib, a proteasome inhibitor, stabilized SUMO2/3 conjugates upon arsenic exposure in Pml-proficient livers or APL (Supplementary Fig. 2d and Supplementary Fig. 4b below). The gene discussed is SUMO2; the disease is acute promyelocytic leukemia.